Findings from a phase 3 trial with Blenrep, Velcade and dexamethasone in relapsed/refractory multiple myeloma will be ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects multi-blockbuster ...

UK drugmaker GSK might be trading lower following Thursday’s nomination of vaccine sceptic Robert F Kennedy Jr as the USA’s ...

GSK's phase 3 GLISTEN trial demonstrated linerixibat's potential to treat relentless itch in PBC patients, meeting its ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

The key secondary end point of overall survival (OS) was met in the DREAMM-7 trial of belantamab mafodotin (Blenrep; GSK) for the treatment of patients with relapsed/refractory multiple myeloma (R/R ...

GSK has announced positive headline interim analysis outcomes from a Phase III trial, which is evaluating Blenrep (belantamab ...

On Thursday, GSK plc (NYSE:GSK) released headline results from a planned interim analysis of the DREAMM-7 head-to-head phase ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an increase in overall survival (OS) with the drug had reached statistical ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep ...

GSK (GSK) announced positive headline results from a planned interim analysis of the DREAMM-7 head-to-head phase III trial evaluating Blenrep in combination with bortezomib plus dexamethasone as a ...